Table 2 Impact of the COVID-19 pandemic on clinical symptoms, hospital visits and medication usage
From: Impact of the COVID-19 pandemic on migraine in Japan: a multicentre cross-sectional study
|  | Migraine patients (n = 606) |
|---|---|
Stress, n (%) | |
 Decreased | 30 (5.0) |
 Unchanged | 232 (38.3) |
 Increased | 344 (56.8) |
Physical activity, n (%) | |
 Decreased | 305 (50.3) |
 Unchanged | 268 (44.2) |
 Increased | 33 (5.4) |
 Impact of COVID-19 epidemic on daily life, n (%) | 273 (45.0) |
Interest in COVID-19, n (%) | |
 None | 1 (0.2) |
 Very little | 3 (0.5) |
 Little | 37 (6.1) |
 Moderate | 139 (22.9) |
 Strong | 426 (70.3) |
Concerns about COVID-19, n (%) | |
 None | 4 (0.7) |
 Very minor | 10 (1.7) |
 Minor | 83 (13.7) |
 Moderate | 175 (28.9) |
 Great | 334 (55.1) |
PGIC scale (1–7) | |
 Mood | 4.5 ± 0.9 |
 Sleep | 4.4 ± 0.99 |
aAcute headache treatment, n (%) | |
 Decreased | 53 (8.7) |
 Unchanged | 367 (60.6) |
 Increased | 186 (30.7) |
Addition or changes in headache-prevention medications, n (%) | 94 (15.5) |
Occupation, n (%) | |
 Frontline worker | 193 (31.8) |
 Working from home | 224 (37.0) |
 Other occupations | 189 (31.2) |
Problems with hospital access, n (%) | 95 (15.7) |
Medication shortage, (n%) | 43 (7.1) |
Received online medical care | |
 Yes, n (%) | 95 (15.7) |
- If yes, what are the advantages and disadvantages? | |
 Advantages | |
  Infection risk reduction | 91 (95.8) |
  Able to continue working | 22 (23.2) |
  Remain with children | 10 (10.5) |
  Others | 13 (13.7) |
 Disadvantages | |
  Short examination times | 35 (36.8) |
  Time schedule conflicts | 4 (4.2) |
  Unfamiliar with the method | 4 (4.2) |
  None | 48 (50.5) |
  Others | 5 (5.3) |
No, n (%) | 511 (95) |
 - If no, would you like to receive telephone/online care in the future? | 264 (51.7) |